Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daishi Shimada has a total of 295 co-authors. Here are the top co-authors by number of shared publications:

  • Masafumi Seki

    Division of Infectious Diseases and Infection Control, Saitama Medical University International Medical Center, Hidaka City, Saitama, Japan

    7 shared publications
  • Masafumi Seki

    4 shared publications
  • Haruka Imai

    Division of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi 983-8512, Japan

    2 shared publications
  • Jun Suzuki

    Division of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi 983-8512, Japan

    2 shared publications
  • Maya Hariu

    Division of Infectious Diseases and Infection Control, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi, Japan

    2 shared publications
  • Mitsuo Kaku

    Division of Infectious Diseases, Tohoku Medical and Pharmaceutical University Hospital, Sendai City, Miyagi 983-8512, Japan

    2 shared publications

Latest Publications

  • Open Access

    Assessing the Lower Incidence of Invasive Pneumococcal Diseases in Japan During the COVOD-19 Pandemic

    by Masafumi Seki, Daishi Shimada

    During the COVID-19 pandemic from 2020 to 2023 in Japan, in our hospital there were seven cases of invasive pneumococcal diseases (IPDs) in this COVID-19 pandemic period although 14 IPD cases were treated in 2019, 2024, and 2025, such as pre-/post- COVID-19 pandemic period. Of these total 21 IPD patients, five (23.8%) died, and they were all treated during pre-/post-pandemic period. Only 2 of the 21 patients (9.5%) children had been vaccinated. Furthermore, compared with survivors, those who died were younger (54.0 vs 69.4 years old, p = 0.0011), had lower white blood cell counts (3672.1 vs 12117.3/μL, p = 0.0011), and had higher C-reactive protein levels (34.5 vs 22.1 mg/dL, p = 0.0010). Two or more bacteria were isolated, and multiple and/or broad antimicrobial agents were used in fatal cases. These data suggested that IPD cases decreased and might have been less pathogenic during the COVID-19 pandemic period than in the pre-/post-COVID-19 pandemic period. In addition, those who died were younger, more septic due to multiple bacterial infections, and received more and broader antimicrobial agents than survivors. No adult patients received pneumococcal vaccination, which suggests that low vaccination rates lead to the high mortality of adult IPD patients.

  • Open Access

    Severe Influenza Patients Who Received Ventilator Management During the 2024 to 2025 Major Influenza-Endemic Season in a Tertiary Hospital in Japan

    by Masafumi Seki, Daishi Shimada

    Three cases of severe influenza that required ventilator management in the 2024– 2025 season, which was a major influenza season in Japan, are presented. Case 1: A 54-year-old man with obesity developed lobar pneumonia as a result of severe community-acquired pneumonia (CAP) secondary to methicillin-susceptible Staphylococcus aureus (MSSA), as confirmed on sputum culture. The nasal swab was positive for influenza A antigen. Intravenous peramivir and piperacillin/tazobactam were administered for 2 days followed by lascufloxacin and linezolid for 2 weeks. Veno-venous extracorporeal membrane oxygenation (VV-ECMO) was also performed. Case 2: A 63-year-old man with multiple myeloma and chronic kidney disease developed severe pneumonia as a result of CAP. Although influenza A antigen was detected, no bacteria were isolated from his specimens. He showed severe hypoxia and massive ground-glass opacities (GGOs) in both lung fields, but he recovered after administration of peramivir and levofloxacin with prednisolone for 2 days and 2 weeks, respectively, with non-invasive positive pressure support. Case 3: A 43-year-old man without any related medical history developed severe heart failure with mild bronchopneumonia and was admitted to our hospital. Acute heart failure caused by myocarditis and CAP due to influenza A were suspected and treated effectively with peramivir and a percutaneous ventricular assist device (IMPELLA), which involved an auxiliary circulating pump with veno-arterial ECMO (VA-ECMO) for 1 day and 2 weeks, respectively. In three middle-aged patients, influenza virus may have accelerated pneumonia/heart failure. All three patients had not received influenza vaccines and were not elderly. Although the emphasis on most vaccines has decreased after the COVID-19 pandemic appears to have subsided, we should stress the importance of influenza vaccines and improvement of critical care protocols, because severe influenza can be a concern for young and middle-aged adults during the influenza season after the post COVID-19 pandemic period.


  • Open Access

    Severe Respiratory Syncytial Virus Infections in Elderly Persons During the COVID-19 Pandemic

    by Daishi Shimada, Masafumi Seki

    Background: Respiratory syncytial virus (RSV) is a pathogenic respiratory virus that is considered to affect not only children but also adults, especially elderly persons aged ≥ 65 years. However, in Japan, the annual epidemic situation and severity of RSV infections in these adults have not yet been clarified, especially during the COVID-19 pandemic. Methods: The epidemic of RSV, especially the number of adults with RSV infection during the COVID-19 period, was retrospectively analyzed. In addition, the clinical features of patients aged ≥ 65 years (older group) and those aged ≤ 64 years (younger group) were compared. Results: A total of 58 patients were found to have RSV infections from April to August 2021. Ten were adults, and five each were detected in June and July, respectively. Of the 10 adult patients, three were in the older group and were more often infected by their grandchildren, and seven were in the younger group. All older patients had underlying diseases, including diabetes mellitus. In addition, the older group showed more severe inflammation, such as increased white blood cell counts and C-reactive protein levels, and received antibiotic therapy, whereas no antibiotics were used for the younger group. Two of the three older patients were admitted to our hospital, but survived. Conclusion: These data suggest that RSV infection in adult patients was related to the increase in pediatric RSV patients and that the infection season had shifted to summer, similar to other countries. Among the adult RSV patients, those aged ≥ 65 years were more often infected by their grandchildren and received antibiotics because of their more severe inflammatory status than patients aged ≤ 64 years during the COVID-19 pandemic in Japan.


  • Open Access

    Effectiveness of Drip Infusion of Lascufloxacin, a Novel Fluoroquinolone Antibiotic, for Patients with Pneumonia Including Chronic Lung Disease Exacerbations and Lung Abscesses

    by Daishi Shimada, Masafumi Seki

    Background: Lascufloxacin (LSFX), a novel fluoroquinolone antibacterial agent, has recently been used as a drip infusion for treating pneumonia, apparently with good effectiveness against various bacteria, including anaerobes, and good intrapulmonary penetration. Methods: The clinical effectiveness of LSFX was retrospectively investigated for the 55 patients admitted to our hospital with pneumonia, including chronic lung disease exacerbations and lung abscesses, from May 2021 to July 2023. Results: The median age of the 55 patients was 76.1 (34.1– 93.1) years, 45 (81.8%) were male, and 48 (87.5%) patients had underlying disease. Community-acquired pneumonia was seen in 47 (85.5%) patients, including 9 (16.4%) with lung abscess, and the other 8 (14.5%) had nursing and healthcare-associated pneumonia/hospital-acquired pneumonia. Moderate pneumonia was present in 33 (61.8%) of 55 patients, and LSFX was used as a second-line treatment for 28 (50.9%) patients in whom first-line antibiotics were ineffective. The median duration of intravenous LSFX administration was 9 (2.0– 49) days. Streptococcus pneumoniae and methicillin-susceptible Staphylococcus aureus were isolated from 3 (7.1%) and 2 (4.8%) patients, respectively. Of the 55 patients, 45 (81.5%) improved clinically with intravenous LSFX administration; 20 (95.2%) of 21 community-acquired pneumonia cases, including 9 (100.0%) of 9 bacterial pneumonia cases, were improved by LSFX as first-line treatment, and 8 (88.9%) of 9 lung abscess patients also showed clinical improvement with LSFX as a second-line treatment. There were no severe adverse effects in any of the 55 patients. Conclusion: Based on these data, intravenous administration of LSFX seems effective for bacterial pneumonia, including chronic lung disease exacerbations and lung abscesses, and it appears to have broad antimicrobial activity and good tissue penetration into the lung.


  • Open Access

    Detection of Mycobacterium avium-intracellulare Complex (MAC) by Bronchial Lavage and the Relationship with Titers of Anti-Glycopeptidolipid-Core IgA Antibodies to MAC in Patients with Pulmonary MAC Disease

    by Daishi Shimada, Motoyasu Sagawa, Masafumi Seki

    Background: Higher rates of diagnosis of pulmonary Mycobacterium avium-intracellulare complex (MAC) disease by bronchoscopy (BS) in patients who could not diagnose by sputum cultures have been suggested, but the detailed utility of BS, especially in combination with anti-glycopeptidolipid-core IgA antibodies (anti-MAC Ab), is still unclear. Methods: A total of 111 patients at our hospital with suspected MAC who underwent BS because they were sputum-negative from April 2018 to March 2022 were analyzed prospectively. These patients were also divided into two groups, anti-MAC Ab-positive and anti-MAC Ab-negative, and compared. Results: A total of 111 patients underwent BS, though 95 (38.0%) of 250 enrolled patients were sputum smear/culture-positive. The age of the 111 patients was 69.14 (31.0– 89.0) years, and 90 (81.0%) were female; 69 (62.2%) of 111 patients were either smear-positive (n = 42, 37.8%) or culture-positive (n = 27, 24.3%) by BS. Of the total 111 patients, 69 (62.2%) were anti-MAC Ab-positive and 57 (82.6%) of 69 patients were also positive by BS. In contrast, only 12 (28.6%) of the 42 anti-MAC Ab-negative patients were positive by BS. The sensitivity and specificity of anti-MAC Ab for positive by BS were 82.6% and 71.4%, respectively, and the area under the curve (AUC) on receiver-operating characteristic (ROC) curve analysis was 0.807. Conclusion: BS and anti-MAC Ab showed similar usefulness to confirm the diagnosis in patients who could not be diagnosed by sputum examination, but pulmonary MAC disease was strongly suspected based on chest radiography/CT findings. These two examinations were correlated, and their combination appeared to provide more accurate diagnosis and earlier therapy.


  • Top Cited Papers

    Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

    by Hugh Montgomery, F D Richard Hobbs, Francisco Padilla, Douglas Arbetter, Alison Templeton, Seth Seegobin, Kenneth Kim, Jesus Abraham Simón Campos, Rosalinda H Arends, Bryan H Brodek, et al.


  • Open Access

    Use of a multiplex polymerase chain reaction assay for the early detection of an outbreak of human parainfluenza virus type 3 infection in a nursery school during the COVID-19 pandemic

    by Jun Suzuki, Shiro Endo, Tomoki Mizuno, Shota Takahashi, Yukiko Horiuchi, Yuri Ami, Haruka Imai, Daishi Shimada, Makiko Yoshida, Mitsuo Kaku, et al.


  • Clinical Characteristics of Adult COVID-19 Pneumonia and Other Viral Pneumonias: Comparisons of Imaging Findings

    by Daishi Shimada, Masafumi Seki

    Different viral infections show characteristic imaging findings based on their particular pathophysiology. SARS-COV-2 shows characteristically high transmissibility and virulence, and it can evade the human immune system. COVID-19 patients frequently develop severe illness involving cytokine storm leading to acute respiratory distress syndrome (ARDS), as well as alveolar flood and severe vascular damage resulting in sepsis and organ damage. These basically develop from bilateral ground-glass infiltrations that are also found in the adult viral pneumonias, such as measles, respiratory syncytial virus, human metapneumovirus, and cytomegalovirus pneumonias. Secondary bacterial pneumonia due to co-infection with bacteria is a major issue in viral pneumonia, especially in influenza pneumonia, but patients with adult viral pneumonias are very different from bacterial pneumonia patients, and they are usually young, produce less sputum, and sometimes show characteristic skin lesions, including rash and vesicular lesions. Accurate diagnosis of the specific pathogen of viral pneumonia is important to perform the appropriate treatment and prevent infection, and it can recently be performed by multiplex PCR.

  • Open Access

    Utility of a Cell-Direct Polymerase Chain Reaction-Based Nucleic Acid Lateral Flow Immunoassay for Detection of Bacteria in Peripheral Blood Leukocytes of Suspected Sepsis Cases

    by Haruka Imai, Yuji Watanabe, Daishi Shimada, Jun Suzuki, Shiro Endo, Mitsuo Kaku, Masafumi Seki

    Background: The detection of the pathogens in the blood is essential for the management of septic patients; however, conventional blood culture takes 2– 3 days. Therefore, rapid and convenient methods may be useful to aid clinical decision-making. Methods: Blood samples with sepsis clinically diagnosed in cases that fulfilled the diagnostic criteria were used and analyzed the utility of a novel bacterial nucleic acid identification test using a cell-direct polymerase chain reaction (cdPCR)-based nucleic acid lateral flow immunoassay (NALFIA) which were named as “DiagnoSep” to detect representative bacteria in peripheral blood leukocytes in patients admitted to our hospital and compared the conventional blood culture results simultaneously taken from the patients. Results: We analyzed the total 42 samples in the terms of this study and found 18 (42.8%) were positive on cdPCR-NALFIA, and 24 (57.1%) were positive on blood cultures. Although the positive rate was higher with blood cultures, 15 samples showed positive results from both blood cultures and cdPCR-NALFIA, and the identified bacteria agreed for 10 samples. Of the 18 cdPCR-NALFIA-positive cases, the results for 8 samples differed from the results of blood cultures; four of them had an implanted pacemaker or prosthetic joint and were positive for Staphylococcus aureus or Staphylococcus epidermidis on cdPCR-NALFIA. Conclusion: Blood culture tests are probably the gold standard in identifying causative organisms in sepsis, but the rapid results from cdPCR-NALFIA simultaneously used with blood culture may make it an important auxiliary diagnostic tool for identifying infecting organisms and lead to the improvement of mortality of the septic patients, because these combined results provide the wide information on the possible pathogens in early phase.


  • A Household Microsporum canis Dermatophytosis Suggested by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry Analysis

    by Maya Hariu, Yuji Watanabe, Daishi Shimada, Haruka Imai, Kauki Takano, Yasuhiro Kamioka, Masafumi Seki

    A Household Microsporum canis Dermatophytosis Suggested by Matrix-Assisted Laser Desorption/Ionization Time-Of-Flight Mass Spectrometry Analysis - Article abstract #930713